首页> 美国卫生研究院文献>OncoTargets and therapy >Expression of microRNA-30c via lentivirus vector inhibits the proliferation and enhances the sensitivity of highly aggressive ccRCC Caki-1 cells to anticancer agents
【2h】

Expression of microRNA-30c via lentivirus vector inhibits the proliferation and enhances the sensitivity of highly aggressive ccRCC Caki-1 cells to anticancer agents

机译:通过慢病毒载体表达microRNA-30c可抑制增殖并增强高度侵袭性ccRCC Caki-1细胞对抗癌药的敏感性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The clear cell renal cell carcinoma (ccRCC) is one of the most fatal urologic tumors, and the prognosis remains very poor for advanced or metastatic ccRCC. This study reveals the roles of microRNA (miR)-30c in regulating a highly aggressive ccRCC cell line proliferation by targeting MTA-1, which is a key mediator for human cancer metastasis. Results from quantitative real-time polymerase chain reaction showed that the expression of MTA-1, the target of miR-30c, was significantly higher in metastatic ccRCC specimens than in nonmetastatic ccRCC or nontumor specimens. Accordingly, endogenous miR-30c is at a much lower level in highly aggressive ccRCC Caki-1 cells than nontumor or ccRCC cell lines. Expression of miR-30c via lentivirus vector inhibits the proliferation, anchorage-independent growth, in vitro invasion or migration, or in vivo growth of Caki-1 cells by repressing MTA-1 protein expression. miR-30c also enhances the sensitivity of Caki-1 cells to anticancer agents, including sorafenib and paclitaxel. These data reveal the potential application of miR-30c and that its targeting gene, MTA-1, would be a potential target in metastatic ccRCC treatment.
机译:透明细胞肾细胞癌(ccRCC)是最致命的泌尿外科肿瘤之一,晚期或转移性ccRCC的预后仍然很差。这项研究揭示了通过靶向MTA-1来调控microRNA(miR)-30c在调节高度侵袭性ccRCC细胞系增殖中的作用,MTA-1是人类癌症转移的关键介质。实时定量聚合酶链反应的结果表明,miR-30c靶标MTA-1的表达在转移性ccRCC标本中明显高于非转移性ccRCC或非肿瘤标本。因此,在高度侵袭性的ccRCC Caki-1细胞中,内源性miR-30c的水平要比非肿瘤或ccRCC细胞系低得多。通过慢病毒载体表达miR-30c可通过抑制MTA-1蛋白表达来抑制Caki-1细胞的增殖,不依赖锚定的生长,体外侵袭或迁移或体内生长。 miR-30c还可以增强Caki-1细胞对包括索拉非尼和紫杉醇在内的抗癌药的敏感性。这些数据揭示了miR-30c的潜在应用,其靶向基因MTA-1将成为转移性ccRCC治疗的潜在靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号